What Is It and How Does It Work?
KX-826 is a topical tincture (1.0% concentration) that you apply directly to your thinning scalp.
It works through a process called Topical Androgen Receptor Antagonism:
-
The Root of the Problem: In pattern baldness, a hormone called DHT binds to receptors inside your hair follicles, slowly shrinking them until they can no longer grow hair.
-
Competing for the Receptor: KX-826 acts like a molecular shield. When applied to the scalp, it physically sits on the androgen receptors and blocks DHT from ever attaching to the follicle.
-
No Hormonal Side Effects: Unlike traditional oral medications (like finasteride or dutasteride) which suppress hormone production throughout your entire body, KX-826 acts strictly locally. Even if a tiny amount of the drug escapes into the bloodstream, it is rapidly broken down into inactive, harmless metabolites. This localized action prevents the systemic or sexual side effects often associated with standard hair-loss drugs.
The Science: Significant Regrowth Confirmed by Phase 3 Clinical Data
The definitive results from the Phase 3 trial in China were presented at the World Congress for Hair Research (WCHR) in June 2026, where the study was recognized as an “Outstanding Poster”.
-
10.65 Hairs/cm² Density Increase: Over the course of the 24-week trial, male patients applying the 1.0% formulation twice daily saw an average increase of 10.65 terminal (thick) hairs per square centimeter compared to those using a placebo.
-
Synergistic Combination Power: A separate clinical observational study presented at the congress showed that combining KX-826 with topical minoxidil produced an even stronger synergistic regrowth effect than using either treatment alone.
-
Impeccable Safety Profile: The incidence of adverse events was highly similar to the placebo group. There were zero drug-related serious adverse events and no drug-related sexual side effects reported during the trials.
“The overall results demonstrated that KX-826 exhibited excellent efficacy and safety in patients with AGA… Upon approval, KX-826 is expected to become a first-in-class topical innovative drug, filling the current clinical gap for new drugs in AGA treatment and breaking the nearly 40-year treatment paradigm.” — Professor Cheng Zhou, Peking University People’s Hospital, Lead Principal Investigator.
When Will It Be Available?
-
Current Stage: The drug developer, Kintor Pharmaceuticals, has finalized its clinical testing and is actively compiling the data to submit its official New Drug Application (NDA) for marketing authorization.
-
Timeline: With regulatory filings imminent as of mid-2026, the treatment is projected to gain formal approval and become commercially available at pharmacies as early as late 2027 or 2028.
How you can benefit from this treatment now
Because KX-826 is still in the final stages of the regulatory approval process, it cannot yet be prescribed by doctors or purchased at pharmacies. However, you can use these Phase 3 insights to guide your current routine:
-
Explore Similar Local Blockers: If you are looking for a localized hormone-blocking approach, ask your doctor about Clascoterone (Breezula). It utilizes a similar receptor-blocking pathway and is also in late-stage Phase 3 clinical testing.
Read next
Whats the best shampoo for hair loss?
-
Optimize a Combination Routine: The latest WCHR 2026 data proved that combining a receptor blocker with a growth-stimulant like minoxidil maximizes regrowth. You can work with a hair specialist today to establish a baseline routine using current standards so that your scalp is healthy and highly receptive by the time KX-826 launches.
-
Avoid Grey-Market Chemicals: Experts strongly advise against purchasing raw “pyrilutamide” powders or liquid mixtures from unregulated online sellers. These unauthorized products lack strict laboratory quality controls, may contain harmful impurities, and can cause severe chemical scalp irritation.
Sources: